213 related articles for article (PubMed ID: 31251311)
1. Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer.
Cheng YA; Chen IJ; Su YC; Cheng KW; Lu YC; Lin WW; Hsieh YC; Kao CH; Chen FM; Roffler SR; Cheng TL
Biomater Sci; 2019 Aug; 7(8):3404-3417. PubMed ID: 31251311
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes.
Chen IJ; Cheng YA; Ho KW; Lin WW; Cheng KW; Lu YC; Hsieh YC; Huang CC; Chuang CH; Chen FM; Su YC; Roffler SR; Cheng TL
Acta Biomater; 2020 Jul; 111():386-397. PubMed ID: 32417267
[TBL] [Abstract][Full Text] [Related]
3. Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer.
Cheng YA; Wu TH; Wang YM; Cheng TL; Chen IJ; Lu YC; Chuang KH; Wang CK; Chen CY; Lin RA; Chen HJ; Liao TY; Liu ES; Chen FM
J Nanobiotechnology; 2020 Aug; 18(1):118. PubMed ID: 32854720
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy.
Lin WW; Cheng YA; Li CC; Ho KW; Chen HJ; Chen IU; Huang BC; Liu HJ; Lu YC; Cheng CM; Huang MY; Lai HW; Cheng TL
Sci Rep; 2021 Apr; 11(1):7598. PubMed ID: 33828191
[TBL] [Abstract][Full Text] [Related]
5. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity.
Ho KW; Chen IU; Cheng YA; Liao TY; Liu ES; Chen HJ; Lu YC; Su YC; Roffler SR; Huang BC; Liu HJ; Huang MY; Chen CY; Cheng TL
J Nanobiotechnology; 2021 Jan; 19(1):16. PubMed ID: 33422061
[TBL] [Abstract][Full Text] [Related]
6. One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles.
Kao CH; Wang JY; Chuang KH; Chuang CH; Cheng TC; Hsieh YC; Tseng YL; Chen BM; Roffler SR; Cheng TL
Biomaterials; 2014 Dec; 35(37):9930-9940. PubMed ID: 25212525
[TBL] [Abstract][Full Text] [Related]
7. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
Shmeeda H; Tzemach D; Mak L; Gabizon A
J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors.
Su CY; Chen M; Chen LC; Ho YS; Ho HO; Lin SY; Chuang KH; Sheu MT
Drug Deliv; 2018 Nov; 25(1):1066-1079. PubMed ID: 29718725
[TBL] [Abstract][Full Text] [Related]
9. Fabrication, characterization, and biological evaluation of anti-HER2 indocyanine green-doxorubicin-encapsulated PEG-b-PLGA copolymeric nanoparticles for targeted photochemotherapy of breast cancer cells.
Lee YH; Chang DS
Sci Rep; 2017 Apr; 7():46688. PubMed ID: 28429764
[TBL] [Abstract][Full Text] [Related]
10. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors.
Akhtari J; Rezayat SM; Teymouri M; Alavizadeh SH; Gheybi F; Badiee A; Jaafari MR
Int J Pharm; 2016 May; 505(1-2):89-95. PubMed ID: 27039149
[TBL] [Abstract][Full Text] [Related]
11. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
12. Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity.
Shrivastava R; Trivedi S; Singh PK; Asif M; Chourasia MK; Khanna A; Bhadauria S
Biochem Biophys Res Commun; 2018 Sep; 503(2):677-683. PubMed ID: 29908185
[TBL] [Abstract][Full Text] [Related]
13. Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer.
Wu SK; Chiang CF; Hsu YH; Lin TH; Liou HC; Fu WM; Lin WL
Int J Nanomedicine; 2014; 9():4485-94. PubMed ID: 25278753
[TBL] [Abstract][Full Text] [Related]
14. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
[TBL] [Abstract][Full Text] [Related]
15. Selective Delivery of PEGylated Compounds to Tumor Cells by Anti-PEG Hybrid Antibodies.
Tung HY; Su YC; Chen BM; Burnouf PA; Huang WC; Chuang KH; Yan YT; Cheng TL; Roffler SR
Mol Cancer Ther; 2015 Jun; 14(6):1317-26. PubMed ID: 25852063
[TBL] [Abstract][Full Text] [Related]
16. Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core-shell-corona nanoparticles.
Tao X; Gou J; Zhang Q; Tan X; Ren T; Yao Q; Tian B; Kou L; Zhang L; Tang X
Biomater Sci; 2018 Jun; 6(7):1869-1881. PubMed ID: 29808221
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells.
Yang T; Choi MK; Cui FD; Lee SJ; Chung SJ; Shim CK; Kim DD
Pharm Res; 2007 Dec; 24(12):2402-11. PubMed ID: 17828616
[TBL] [Abstract][Full Text] [Related]
18. Dual-responsive mPEG-PLGA-PGlu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: an in vitro and in vivo evaluation.
Xu H; Yang D; Cai C; Gou J; Zhang Y; Wang L; Zhong H; Tang X
Acta Biomater; 2015 Apr; 16():156-68. PubMed ID: 25662165
[TBL] [Abstract][Full Text] [Related]
19. Targeted doxorubicin delivery and release within breast cancer environment using PEGylated chitosan nanoparticles labeled with monoclonal antibodies.
Helmi O; Elshishiny F; Mamdouh W
Int J Biol Macromol; 2021 Aug; 184():325-338. PubMed ID: 34119547
[TBL] [Abstract][Full Text] [Related]
20. A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity.
Zhou H; Lv S; Zhang D; Deng M; Zhang X; Tang Z; Chen X
Acta Biomater; 2018 Jun; 73():388-399. PubMed ID: 29694920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
